Amgen Inc. (AMGN)

$325.09

+3.42

(+1.06%)

Market is closed - opens 7 PM, 12 Jul 2024
star icon

Amgen, Inc. is a biopharmaceutical company that is involved in the development and commercialization of drugs for various diseases.

Insights on Amgen Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 8.19B → 7.39B (in $), with an average decrease of 9.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 1.73B → -113.0M (in $), with an average decrease of 85.2% per quarter

  • Vs LLY

    In the last 1 year, Eli Lilly And Company has given 112.0% return, outperforming this stock by 68.0%

  • Vs LLY

    In the last 3 years, Eli Lilly And Company has given 295.8% return, outperforming this stock by 262.8%

Performance

  • $320.48
    $327.82
    $325.09
    downward going graph

    1.42%

    Downside

    Day's Volatility :2.24%

    Upside

    0.83%

    downward going graph
  • $212.66
    $327.99
    $325.09
    downward going graph

    34.58%

    Downside

    52 Weeks Volatility :35.16%

    Upside

    0.88%

    downward going graph

Returns

PeriodAmgen Inc.Sector (Health Care)Index (NASDAQ Composite)
3 Months
21.63%
6.1%
13.0%
6 Months
6.06%
4.9%
22.1%
1 Year
44.05%
13.6%
31.4%
3 Years
33.03%
14.3%
24.1%

Highlights

Market Capitalization
172.6B
Book Value
$9.36
Dividend Share
8.64
Dividend Yield
2.8%
Earnings Per Share (EPS)
7.01
PE Ratio
45.89
PEG Ratio
2.39
Wall Street Target Price
294.27
Profit Margin
12.74%
Operating Margin TTM
13.33%
Return On Assets TTM
4.88%
Return On Equity TTM
72.57%
Revenue TTM
29.5B
Revenue Per Share TTM
55.15
Quarterly Revenue Growth YOY
22.0%
Gross Profit TTM
19.9B
EBITDA
11.7B
Diluted Eps TTM
7.01
Quarterly Earnings Growth YOY
-0.52
EPS Estimate Current Year
17.97
EPS Estimate Next Year
18.91
EPS Estimate Current Quarter
3.87
EPS Estimate Next Quarter
4.98

Analyst Recommendation

Buy
    56%Buy
    35%Hold
    8%Sell
Based on 37 Wall street analysts offering stock ratings for Amgen Inc.(by analysts ranked 0 to 5 stars)
Based on 37 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
21
21
22
Hold
13
13
10
Sell
3
3
3

Analyst Forecast

What analysts predicted

Downside of 9.48%

Current $325.09
Target $294.27

Company Financials

FY18Y/Y Change
Revenue
23.7B
↑ 3.93%
Net Income
8.4B
↑ 324.15%
Net Profit Margin
35.35%
↑ 26.69%
FY19Y/Y Change
Revenue
23.4B
↓ 1.62%
Net Income
7.8B
↓ 6.58%
Net Profit Margin
33.57%
↓ 1.78%
FY20Y/Y Change
Revenue
25.4B
↑ 8.83%
Net Income
7.3B
↓ 7.37%
Net Profit Margin
28.57%
↓ 5.0%
FY21Y/Y Change
Revenue
26.0B
↑ 2.18%
Net Income
5.9B
↓ 18.87%
Net Profit Margin
22.68%
↓ 5.89%
FY22Y/Y Change
Revenue
26.3B
↑ 1.32%
Net Income
6.6B
↑ 11.18%
Net Profit Margin
24.89%
↑ 2.21%
FY23Y/Y Change
Revenue
28.2B
↑ 7.09%
Net Income
6.7B
↑ 2.52%
Net Profit Margin
23.83%
↓ 1.06%
Q4 FY22Q/Q Change
Revenue
6.8B
↑ 2.81%
Net Income
1.6B
↓ 24.59%
Net Profit Margin
23.63%
↓ 8.59%
Q1 FY23Q/Q Change
Revenue
6.1B
↓ 10.73%
Net Income
2.8B
↑ 75.8%
Net Profit Margin
46.54%
↑ 22.91%
Q2 FY23Q/Q Change
Revenue
7.0B
↑ 14.43%
Net Income
1.4B
↓ 51.46%
Net Profit Margin
19.74%
↓ 26.8%
Q3 FY23Q/Q Change
Revenue
6.9B
↓ 1.19%
Net Income
1.7B
↑ 25.45%
Net Profit Margin
25.06%
↑ 5.32%
Q4 FY23Q/Q Change
Revenue
8.2B
↑ 18.73%
Net Income
767.0M
↓ 55.66%
Net Profit Margin
9.36%
↓ 15.7%
Q1 FY24Q/Q Change
Revenue
7.4B
↓ 9.76%
Net Income
-113.0M
↓ 114.73%
Net Profit Margin
-1.53%
↓ 10.89%
FY18Y/Y Change
Total Assets
66.4B
↓ 16.93%
Total Liabilities
53.9B
↓ 1.46%
FY19Y/Y Change
Total Assets
59.7B
↓ 10.1%
Total Liabilities
50.0B
↓ 7.2%
FY20Y/Y Change
Total Assets
62.9B
↑ 5.43%
Total Liabilities
53.5B
↑ 7.01%
FY21Y/Y Change
Total Assets
61.2B
↓ 2.83%
Total Liabilities
54.5B
↑ 1.73%
FY22Y/Y Change
Total Assets
65.1B
↑ 6.47%
Total Liabilities
61.5B
↑ 12.84%
FY23Y/Y Change
Total Assets
97.2B
↑ 49.19%
Total Liabilities
90.9B
↑ 47.94%
Q4 FY22Q/Q Change
Total Assets
65.1B
↑ 2.23%
Total Liabilities
61.5B
↑ 2.35%
Q1 FY23Q/Q Change
Total Assets
88.7B
↑ 36.24%
Total Liabilities
83.4B
↑ 35.65%
Q2 FY23Q/Q Change
Total Assets
90.3B
↑ 1.75%
Total Liabilities
83.5B
↑ 0.14%
Q3 FY23Q/Q Change
Total Assets
90.5B
↑ 0.29%
Total Liabilities
82.9B
↓ 0.73%
Q4 FY23Q/Q Change
Total Assets
97.2B
↑ 7.31%
Total Liabilities
90.9B
↑ 9.71%
Q1 FY24Q/Q Change
Total Assets
93.0B
↓ 4.3%
Total Liabilities
88.0B
↓ 3.26%
FY18Y/Y Change
Operating Cash Flow
11.3B
↑ 1.06%
Investing Cash Flow
14.3B
↓ 456.34%
Financing Cash Flow
-22.5B
↑ 241.07%
FY19Y/Y Change
Operating Cash Flow
9.2B
↓ 19.0%
Investing Cash Flow
5.7B
↓ 60.19%
Financing Cash Flow
-15.8B
↓ 29.89%
FY20Y/Y Change
Operating Cash Flow
10.5B
↑ 14.72%
Investing Cash Flow
-5.4B
↓ 194.61%
Financing Cash Flow
-4.9B
↓ 69.13%
FY21Y/Y Change
Operating Cash Flow
9.3B
↓ 11.77%
Investing Cash Flow
733.0M
↓ 113.57%
Financing Cash Flow
-8.3B
↑ 69.94%
FY22Y/Y Change
Operating Cash Flow
9.7B
↑ 4.97%
Investing Cash Flow
-6.0B
↓ 924.56%
Financing Cash Flow
-4.0B
↓ 51.19%
FY23Y/Y Change
Operating Cash Flow
8.5B
↓ 12.86%
Investing Cash Flow
-26.2B
↑ 333.55%
Financing Cash Flow
21.0B
↓ 621.38%
Q4 FY22Q/Q Change
Operating Cash Flow
2.6B
↓ 11.05%
Investing Cash Flow
-3.5B
↑ 1200.75%
Financing Cash Flow
-1.0B
↓ 166.06%
Q1 FY23Q/Q Change
Operating Cash Flow
1.1B
↓ 59.83%
Investing Cash Flow
1.4B
↓ 139.1%
Financing Cash Flow
21.5B
↓ 2150.43%
Q2 FY23Q/Q Change
Operating Cash Flow
4.1B
↑ 286.18%
Investing Cash Flow
-211.0M
↓ 115.54%
Financing Cash Flow
-1.2B
↓ 105.63%
Q3 FY23Q/Q Change
Operating Cash Flow
2.8B
↓ 32.83%
Investing Cash Flow
-262.0M
↑ 24.17%
Financing Cash Flow
-2.0B
↑ 65.7%
Q4 FY23Q/Q Change
Operating Cash Flow
538.0M
↓ 80.51%
Investing Cash Flow
-27.1B
↑ 10239.31%
Financing Cash Flow
2.8B
↓ 237.36%
Q1 FY24Q/Q Change
Operating Cash Flow
689.0M
↑ 28.07%
Investing Cash Flow
-217.0M
↓ 99.2%
Financing Cash Flow
-1.7B
↓ 162.02%

Technicals Summary

Sell

Neutral

Buy

Amgen Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Amgen Inc.
Amgen Inc.
7.97%
6.06%
44.05%
33.03%
85.84%
Eli Lilly And Company
Eli Lilly And Company
7.71%
45.3%
112.02%
295.81%
762.63%
Johnson & Johnson
Johnson & Johnson
2.95%
-7.81%
-5.3%
-11.67%
11.47%
Merck & Co. Inc.
Merck & Co. Inc.
-0.94%
8.72%
20.01%
66.31%
61.76%
Abbvie Inc
Abbvie Inc
2.3%
4.62%
25.88%
44.44%
141.76%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Amgen Inc.
Amgen Inc.
45.89
45.89
2.39
17.97
0.73
0.05
0.03
9.36
Eli Lilly And Company
Eli Lilly And Company
136.99
136.99
1.43
12.37
0.51
0.13
0.01
14.23
Johnson & Johnson
Johnson & Johnson
22.24
22.24
0.89
9.73
0.24
0.08
0.03
29.09
Merck & Co. Inc.
Merck & Co. Inc.
141.44
141.44
0.1
7.96
0.05
0.1
0.02
15.94
Abbvie Inc
Abbvie Inc
50.04
50.04
0.45
11.19
0.56
0.08
0.04
4.54
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Amgen Inc.
Amgen Inc.
Buy
$172.6B
85.84%
45.89
12.74%
Eli Lilly And Company
Eli Lilly And Company
Buy
$846.2B
762.63%
136.99
17.08%
Johnson & Johnson
Johnson & Johnson
Buy
$359.6B
11.47%
22.24
44.92%
Merck & Co. Inc.
Merck & Co. Inc.
Buy
$322.4B
61.76%
141.44
3.76%
Abbvie Inc
Abbvie Inc
Buy
$296.9B
141.76%
50.04
11.02%

Institutional Holdings

  • Vanguard Group Inc

    9.71%
  • BlackRock Inc

    8.94%
  • State Street Corporation

    5.43%
  • PRIMECAP Management Company

    2.72%
  • Morgan Stanley - Brokerage Accounts

    2.60%
  • Geode Capital Management, LLC

    2.17%

Corporate Announcements

  • Amgen Inc. Dividends March,2024

    In the quarter ending March,2024. Amgen Inc. has declared dividend of $2.25

    Read More

Company Information

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the worlds largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.

Organization
Amgen Inc.
Employees
26700
CEO
Mr. Robert A. Bradway
Industry
Health Technology

FAQs